{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:24:45Z","timestamp":1780374285820,"version":"3.54.1"},"reference-count":39,"publisher":"Impact Journals, LLC","issue":"35","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,11,10]]},"DOI":"10.18632\/oncotarget.5954","type":"journal-article","created":{"date-parts":[[2015,10,5]],"date-time":"2015-10-05T03:46:00Z","timestamp":1444016760000},"page":"37229-37240","source":"Crossref","is-referenced-by-count":24,"title":["Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736"],"prefix":"10.18632","volume":"6","author":[{"given":"Valentina","family":"Restelli","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Pharmacology and Laboratory of Cancer Pharmacology, Department of Oncology, IRCCS- Istituto di Ricerche Farmacologiche \u201cMario Negri\u201d, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaria","family":"Chil\u00e0","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Pharmacology and Laboratory of Cancer Pharmacology, Department of Oncology, IRCCS- Istituto di Ricerche Farmacologiche \u201cMario Negri\u201d, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Lupi","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Pharmacology and Laboratory of Cancer Pharmacology, Department of Oncology, IRCCS- Istituto di Ricerche Farmacologiche \u201cMario Negri\u201d, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rinaldi","sequence":"additional","affiliation":[{"name":"Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Kwee","sequence":"additional","affiliation":[{"name":"Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland"},{"name":"Dalle Molle Institute for Artificial Intelligence (IDSIA), Manno, Switzerland"},{"name":"Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bertoni","sequence":"additional","affiliation":[{"name":"Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland"},{"name":"Lymphoma Unit, IOSI Oncology Institute of Southern Switzerland, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Damia","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Pharmacology and Laboratory of Cancer Pharmacology, Department of Oncology, IRCCS- Istituto di Ricerche Farmacologiche \u201cMario Negri\u201d, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Carrassa","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Pharmacology and Laboratory of Cancer Pharmacology, Department of Oncology, IRCCS- Istituto di Ricerche Farmacologiche \u201cMario Negri\u201d, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,10,2]]},"reference":[{"key":"1","first-page":"229","article-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Lyon: IARC)","author":"Vardiman","year":"2008","journal-title":"Mantle cell lymphoma"},{"key":"2","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2009-02-179739","article-title":"How I treat mantle cell lymphoma","volume":"114","author":"Zucca","year":"2009","journal-title":"Blood"},{"key":"3","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Unterhalt","year":"2009","journal-title":"J Clin Oncol"},{"key":"4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era","volume":"117","author":"Wiestner","year":"2011","journal-title":"Blood"},{"key":"5","doi-asserted-by":"crossref","first-page":"6364","DOI":"10.1200\/JCO.2005.05.019","article-title":"Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways","volume":"23","author":"Rosenwald","year":"2005","journal-title":"J Clin Oncol"},{"key":"6","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.prp.2010.06.006","article-title":"Importance of DNA damage checkpoints in the pathogenesis of human cancers","volume":"206","author":"Roessner","year":"2010","journal-title":"Pathol Res Pract"},{"key":"7","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.4161\/cc.10.13.16398","article-title":"Unleashing Chk1 in cancer therapy","volume":"10","author":"Damia","year":"2011","journal-title":"Cell Cycle"},{"key":"8","doi-asserted-by":"crossref","first-page":"14795","DOI":"10.1073\/pnas.182557299","article-title":"Disruption of the checkpoint kinase 1\/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints","volume":"99","author":"Piwnica-Worms","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1158\/1535-7163.MCT-07-2391","article-title":"Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1","volume":"7","author":"Anderes","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1158\/1535-7163.MCT-11-0406","article-title":"Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites","volume":"11","author":"Eastman","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"11","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1200\/JCO.2014.57.5027","article-title":"Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors","volume":"33","author":"Kang","year":"2015","journal-title":"J Clin Oncol"},{"key":"12","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/nar\/gkr697","article-title":"Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication","volume":"40","author":"Syljuasen","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"13","doi-asserted-by":"crossref","first-page":"16090","DOI":"10.1073\/pnas.1005031107","article-title":"Chk1 promotes replication fork progression by controlling replication initiation","volume":"107","author":"Helleday","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"14","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1038\/sj.emboj.7601714","article-title":"Chk1 regulates the density of active replication origins during the vertebrate S phase","volume":"26","author":"Jackson","year":"2007","journal-title":"EMBO J"},{"key":"15","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1111\/j.1582-4934.2008.00362.x","article-title":"U2OS cells lacking Chk1 undergo aberrant mitosis and fail to activate the spindle checkpoint","volume":"13","author":"Damia","year":"2009","journal-title":"J Cell Mol Med"},{"key":"16","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1073\/pnas.1012351108","article-title":"RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma","volume":"108","author":"Mosse","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"17","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/onc.2012.72","article-title":"A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress","volume":"32","author":"Gabrielli","year":"2013","journal-title":"Oncogene"},{"key":"18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1476-4598-8-24","article-title":"CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors","volume":"8","author":"D'Andrea","year":"2009","journal-title":"Mol Cancer"},{"key":"19","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/onc.2011.358","article-title":"Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells","volume":"31","author":"McArthur","year":"2012","journal-title":"Oncogene"},{"key":"20","doi-asserted-by":"crossref","first-page":"7067","DOI":"10.1158\/1078-0432.CCR-11-1198","article-title":"Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells","volume":"17","author":"Nilsson","year":"2011","journal-title":"Clin Cancer Res"},{"key":"21","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.4161\/cc.20899","article-title":"Combined inhibition of Chk1 and Wee1:synergistic effect translates to tumor growth inhibition","volume":"11","author":"Damia","year":"2012","journal-title":"Cell Cycle"},{"key":"22","doi-asserted-by":"crossref","first-page":"788","DOI":"10.4161\/cbt.12.9.17673","article-title":"Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation","volume":"12","author":"Gross","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1475-2867-12-45","article-title":"Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition","volume":"12","author":"Shumway","year":"2012","journal-title":"Cancer Cell Int"},{"key":"24","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.18632\/oncotarget.2583","article-title":"Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma","volume":"6","author":"Carrassa","year":"2015","journal-title":"Oncotarget"},{"key":"25","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1056\/NEJMe1307596","article-title":"Toward new treatments for mantle-cell lymphoma?","volume":"369","author":"Bertoni","year":"2013","journal-title":"N Engl J Med"},{"key":"26","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/CCO.0b013e328363df0b","article-title":"The current therapeutic scenario for relapsed mantle cell lymphoma","volume":"25","author":"Dreyling","year":"2013","journal-title":"Curr Opin Oncol"},{"key":"27","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1158\/1078-0432.CCR-10-2616","article-title":"Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors","volume":"17","author":"Pandiella","year":"2011","journal-title":"Clin Cancer Res"},{"key":"28","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/bcp.12139","article-title":"The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design","volume":"76","author":"Eastman","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"29","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1158\/1535-7163.MCT-09-0463","article-title":"Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents","volume":"8","author":"Jiang","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"30","first-page":"5106","article-title":"Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase\/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells","volume":"61","author":"Grant","year":"2001","journal-title":"Cancer Res"},{"key":"31","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1182\/blood-2010-06-291146","article-title":"Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cellsand","volume":"117","author":"Grant","year":"2011","journal-title":"Blood"},{"key":"32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0010-468X(85)90007-8","article-title":"Microcomputer experience in analysis of flow cytometric DNA distributions","volume":"19","author":"Ubezio","year":"1985","journal-title":"Comput Programs Biomed"},{"key":"33","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1073\/pnas.80.18.5573","article-title":"Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine","volume":"80","author":"Gray","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"key":"34","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/cyto.990060618","article-title":"A method to measure the duration of DNA synthesis and the potential doubling time from a single sample","volume":"6","author":"Karcher","year":"1985","journal-title":"Cytometry"},{"key":"35","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00280-005-0044-1","article-title":"Interpreting cell cycle effects of drugs: the case of melphalan","volume":"57","author":"Ubezio","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"36","volume-title":"Growth kinetics of tumours: cell population kinetics in relation to the growth and treatment of cancer","author":"Steel","year":"1977"},{"key":"37","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1158\/1078-0432.CCR-14-1561","article-title":"The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs","volume":"21","author":"Inghirami","year":"2015","journal-title":"Clin Cancer Res"},{"key":"38","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Mesirov","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"39","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.0105-2896.2006.00373.x","article-title":"A library of gene expression signatures to illuminate normal and pathological lymphoid biology","volume":"210","author":"Staudt","year":"2006","journal-title":"Immunol Rev"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.5954","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T17:57:16Z","timestamp":1589392636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.5954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,2]]},"references-count":39,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2015,11,10]]}},"alternative-id":["5954","26439697"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.5954","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,2]]}}}